Pancreatic Cancer Research

ResearcherUniversity of FoggiaActive in the last 2 years

Jose Carlos Prados

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4303-7746; OpenAlex author ID A5089503870, A5130990377. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
27
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper

Papers 22

  1. Preclinical evidence for cytokine-based immunotherapy in pancreatic cancer treatment: A systematic review. Co-author DOI 10.1016/j.ijbiomac.2026.153486↗
  2. Computed Tomography-Based Sarcopenia and Pancreatic Cancer Survival-A Comprehensive Meta-Analysis Exploring the Influence of Definition Criteria, Prevalence, a… Last author DOI 10.3390/cancers17040607↗
  3. Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review. Co-author DOI 10.1002/wnan.2013↗
  4. Prevalence of Sarcopenia Determined by Computed Tomography in Pancreatic Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Last author DOI 10.3390/cancers16193356↗
  5. Fungi-Derived Bioactive Compounds as Potential Therapeutic Agents for Pancreatic Cancer: A Systematic Review. Last author DOI 10.3390/microorganisms12081527↗
  6. Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer. Co-author DOI 10.2147/ijn.s415631↗
  7. Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review. Co-author DOI 10.3390/metabo13070872↗
  8. PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine. Co-author DOI 10.1016/j.biopha.2022.113669↗
  9. Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress. Last author DOI 10.3390/cancers13092058↗
  10. The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study. Co-author DOI 10.3390/cancers13133169↗
  11. Liquid biopsy approach to pancreatic cancer. Co-author DOI 10.4251/wjgo.v13.i10.1263↗
  12. Nanomedicine in Pancreatic Cancer: A New Hope for Treatment. Last author DOI 10.2174/1389450121666200703195229↗
  13. Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics. Co-author DOI 10.3390/cancers12041002↗
  14. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview. Last author DOI 10.20892/j.issn.2095-3941.2019.0252↗
  15. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. Last author DOI 10.1371/journal.pone.0194844↗
  16. Proteomic biomarkers in body fluids associated with pancreatic cancer. Co-author DOI 10.18632/oncotarget.24654↗
  17. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study. Co-author DOI 10.1177/1087057116671490↗
  18. Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients. Last author DOI 10.1016/j.taap.2016.10.003↗
  19. Current Status of Immunotherapy Treatments for Pancreatic Cancer. First author DOI 10.1097/mcg.0000000000000623↗
  20. Prognosis Relevance of Serum Cytokines in Pancreatic Cancer. Co-author DOI 10.1155/2015/518284↗
  21. Transcriptional profiling of peripheral blood in pancreatic adenocarcinoma patients identifies diagnostic biomarkers. First author DOI 10.1007/s10620-014-3291-3↗
  22. Serum cytokine profile in patients with pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000155↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Consolación Melguizo Alonso · 17 shared papers, 2014–2026 · strength 2.86
  2. Francisco Quiñonero · 9 shared papers, 2019–2026 · strength 1.77
  3. Raúl Ortíz · 9 shared papers, 2014–2024 · strength 1.37
  4. Cristina Jiménez‐Luna · 12 shared papers, 2014–2023 · strength 1.30
  5. Gloria Perazzoli · 6 shared papers, 2019–2023 · strength 0.91
  6. Octavio Caba · 9 shared papers, 2014–2021 · strength 0.68
  7. Antonio Jesús Láinez Ramos‐Bossini · 3 shared papers, 2020–2025 · strength 0.61
  8. Carolina Torres · 8 shared papers, 2014–2021 · strength 0.55
  9. Antonio Gámez Martínez · 2 shared papers, 2024–2025 · strength 0.50
  10. Jorge Rodríguez-Criado · 1 shared paper, 2026 · strength 0.39
  11. Joaquina Martínez-Galán · 4 shared papers, 2015–2021 · strength 0.39
  12. Kevin Doello González · 3 shared papers, 2019–2021 · strength 0.35
  13. Patricia Lara · 1 shared paper, 2024 · strength 0.28
  14. Sonia Perales Romero · 4 shared papers, 2014–2021 · strength 0.26
  15. Antonio Irigoyen · 5 shared papers, 2014–2018 · strength 0.25
  16. José Pérez del Palacio · 2 shared papers, 2017–2020 · strength 0.18
  17. Jose Manuel Sanchez-Manas · 1 shared paper, 2021 · strength 0.15
  18. Manuel Benavides · 2 shared papers, 2016–2018 · strength 0.13
  19. Javier Gallego-Plazas · 2 shared papers, 2016–2018 · strength 0.13
  20. Carmen Guillén‐Ponce · 2 shared papers, 2016–2018 · strength 0.13
  21. Enrique Aranda Aguilar · 2 shared papers, 2016–2018 · strength 0.13
  22. Antonia Aránega · 3 shared papers, 2014–2015 · strength 0.12
  23. Ana Linares · 3 shared papers, 2014–2015 · strength 0.12
  24. Pablo Redruello Guerrero · 1 shared paper, 2020 · strength 0.11
  25. Ariadna Martín-Blázquez · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.